Skip to content

Withdraw due to duplicate registration. Long-term therapeutic evaluation of two types of platelet-rich plasma treatments for early knee osteoarthritis in middle-aged patients (PORT): a prospective, double-blind, randomised, Chinese multi-centre clinical trial

Long-term therapeutic evaluation of two types of platelet-rich plasma treatments for early knee osteoarthritis in middle-aged patients (PORT): a prospective, double-blind, randomised, Chinese multi-centre clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033513
Enrollment
Unknown
Registered
2020-06-03
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Control Group: Inject Saline
L-PRP Group: Inject L-PRP

Sponsors

Shanghai Sixth People's hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: All consenting knee OA patients meeting the following criteria are screened for inclusion: 1. between the ages of 40 years and 70 years old (non-inclusive); 2. who have had bilateral knee pain persisting for more than 6 months (also present for most of previous month); 3. have Kellgren and Lawrence grade 2 or 3 knee OA (documented by anteroposterior and lateral view X-rays); 4. have completed physical therapy for at least 3 months; and 5. are able to communicate in Mandarin Chinese.

Exclusion criteria

Exclusion criteria: 1. Candidate participant has co-morbidities, such as systemic or inflammatory joint disease (rheumatoid arthritis); history of crystalline arthritis (gout and pseudogout) or neurological joint disease (neuroarthropathies, Charcot joint); other muscle, joint, or nervous system diseases that affect lower limb function; 2. has needle phobia; 3. has evidence of immunosuppression or acute infection; 4. has or has had cancer or tumours; 5. has a bleeding disorder or is receiving anticoagulation or antiplatelet therapy; 6. has a platelet count of = 6.2 mmol/L and triglycerides of >2.3 mmol/L; 8. presence of other medical conditions that preclude participation, including contraindications to MRI, such as pacemaker, ferromagnetic aneurysm clips, cochlear implant, or any other metallic foreign bodies; 9. pregnant; 10. has a body mass index (BMI) of > 40 kg/m2; 11. unable to make at least 10 research appointments within 24 months; 12. has a history of any mental illness.

Design outcomes

Primary

MeasureTime frame
WOMAC scale;Volume of medial tibial cartilage;

Secondary

MeasureTime frame
Severity of knee pain during walking;Intermittent and persistent osteoarthritis pain;Knee joint injury and OA outcome score;The amount of celecoxib taken orally;

Countries

China

Contacts

Public ContactZhang Changqing

Shanghai Sixth People's hospital

zhangcq@sjtu.com+86 13003104089

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026